GSA Capital Partners’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

GSA Capital Partners’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,440	Closed	-$205K	–	1977
2017 Q2	$205K	Buy	+1,440	New	+$223K	0.01%	1495
2017 Q1	–	Sell	-1,680	Closed	-$135K	–	2109
2016 Q4	$135K	Buy	1,680 +797	+90%	+$63K	0.01%	1658
2016 Q3	$68K	Buy	+883	New	+$70.7K	﹤0.01%	1719
2015 Q2	–	Sell	-1,201	Closed	-$880K	–	2278
2015 Q1	$880K	Buy	+1,201	New	+$902K	0.04%	970

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GSA Capital Partners's TTPH Position: Q3 2017 in Review

GSA Capital Partners sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2017, closing a stake of 1,440 shares — an estimated $205K sold.

GSA Capital Partners first reported a position in TTPH in Q1 2015 and held it in 4 quarters. The position peaked at $880K in Q1 2015. 94 funds tracked by Wall St. Rank hold TTPH as of Q3 2017.

GSA Capital Partners reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
GSA Capital Partners sold 1,440 Tetraphase Pharmaceuticals, Inc. shares in Q3 2017, an estimated $205K.
GSA Capital Partners first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2015 and held it in 4 quarters.
GSA Capital Partners's Tetraphase Pharmaceuticals, Inc. position peaked at $880K in Q1 2015.
94 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2017.

Based on GSA Capital Partners's 13F filing for Q3 2017, filed 20 Nov 2017.